Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer

Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy

“…Enzalutamide is a potent inducer of the cytochrome P450 (CYP) family such as CYP3A4 and a moderate inducer of CYP2C19 and CYP2C9. In vitro evidence shows that enzalutamide also induces CYP2B6 and uridine 5′-diphospho-glucuronosiltransferase 1A1/4 (UGT1A1/4), contributing to antiretroviral metabolism [ 14 ]. Hence, if ritonavir and enzalutamide are administered to the same patient, such as in the case of Patient 2, a lower efficacy of ritonavir could be seen.…”

COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature

“…205 articles were identified and reviewed independently by two authors (EL AND RDT) and 53 articles were considered relevant to the scope of the current review, as described in Fig. 1 (Zhang et al, 2000;Mohile et al, 2020;AminJafari and Ghasemi, 2020;Salako et al, 2020;Russell et al, 2020;De Felice et al, 2020, Akladios et al 2020, Banna et al, 2020Al-Shamsi et al, 2020;Zhang et al, 2020;Hanna et al, 2020;Ying et al, 2015;Coles et al, 2020;Debureaux et al, 2020;Di Saverio et al, 2020;Givi et al, 2020;Jin et al, 2020;Bersanelli, 2020;Ueda et al, 2020;Deng et al, 2020;Liang et al, 2020;Combs et al, 2020;Wang et al, 2020a;Zaorsky et al, 2020;Lim et al, 2020;Kalil, 2020;Wang et al, 2020b;Stebbin et al, 2020;Yang et al, 2020;Yu et al, 2020;Williams et al, 2020;Sheahan et al, 2020;Gautret et al, 2020;Chatre et al, 2018;Nhean et al, 2018;Gerson et al, 2018;Naqash et al, 2018;La Regina et al, 2019;Zheng et al, 2020;…”

“…Enzalutamide, androgen receptor signaling inhibitors (ARSI), commonly used in prostate cancer could potentially interfere with antiviral drugs due to interference on cytochromes (Nhean et al, 2018).…”

Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report

“…Enzalutamide is an oral, competitive androgen receptor inhibitor of the androgen receptor translocation to the cell nucleus that has proven to be an effective agent for the management of metastatic prostate cancer [3]. Although enzalutamide is efficacious and carries a favorable adverse effect profile, it might create clinical challenges in PWH for its potential to cause drug-drug interactions (DDIs) with some antiretrovirals [4].…”